Education
About Us
Working with TipRanks
Follow Us
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
Total Valuation
Aurinia Pharmaceuticals has a market cap or net worth of $1.12B. The enterprise value is ―.
Market Cap$1.12B
Enterprise Value―
Share Statistics
Aurinia Pharmaceuticals has 135,104,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding135,104,310
Owned by Insiders10.67%
Owned by Institutions18.08%
Financial Efficiency
Aurinia Pharmaceuticals’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is -0.77%.
Return on Equity (ROE)0.02
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)-0.77%
Return on Capital Employed (ROCE)-0.01
Revenue Per Employee1.81M
Profits Per Employee44.25K
Employee Count130
Asset Turnover0.43
Inventory Turnover0.72
Valuation Ratios
The current PE Ratio of Aurinia Pharmaceuticals is 223.34. Aurinia Pharmaceuticals’s PEG ratio is 1.64.
PE Ratio223.34
PS Ratio0.00
PB Ratio3.12
Price to Fair Value3.40
Price to FCF25.80
Price to Operating Cash Flow26.54
PEG Ratio1.64
Income Statement
In the last 12 months, Aurinia Pharmaceuticals had revenue of 235.13M and earned 5.75M in profits. Earnings per share was 0.04.
Revenue235.13M
Gross Profit206.88M
Operating Income-4.69M
Pretax Income7.45M
Net Income5.75M
EBITDA31.73M
Earnings Per Share (EPS)0.04
Cash Flow
In the last 12 months, operating cash flow was 44.41M and capital expenditures -280.32K, giving a free cash flow of 44.13M billion.
Operating Cash Flow44.41M
Free Cash Flow44.13M
Free Cash Flow per Share0.33
Dividends & Yields
Aurinia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change58.73%
50-Day Moving Average8.06
200-Day Moving Average7.80
Relative Strength Index (RSI)55.70
Average Volume (3m)1.21M
Important Dates
Aurinia Pharmaceuticals upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Aurinia Pharmaceuticals as a current ratio of 4.57, with Debt / Equity ratio of 21.03%
Current Ratio4.57
Quick Ratio4.17
Debt to Market Cap0.06
Net Debt to EBITDA-0.13
Interest Coverage Ratio-0.97
Taxes
In the past 12 months, Aurinia Pharmaceuticals has paid 1.70M in taxes.
Income Tax1.70M
Effective Tax Rate0.23
Enterprise Valuation
Aurinia Pharmaceuticals EV to EBITDA ratio is 40.36, with an EV/FCF ratio of 29.03.
EV to Sales5.45
EV to EBITDA40.36
EV to Free Cash Flow29.03
EV to Operating Cash Flow28.85
Balance Sheet
Aurinia Pharmaceuticals has $358.48M in cash and marketable securities with $79.37M in debt, giving a net cash position of -$279.11M billion.
Cash & Marketable Securities$358.48M
Total Debt$79.37M
Net Cash-$279.11M
Net Cash Per Share-$2.07
Tangible Book Value Per Share$2.61
Margins
Gross margin is 87.99%, with operating margin of -1.99%, and net profit margin of 2.45%.
Gross Margin87.99%
Operating Margin-1.99%
Pretax Margin3.17%
Net Profit Margin2.45%
EBITDA Margin13.49%
EBIT Margin5.22%
Analyst Forecast
The average price target for Aurinia Pharmaceuticals is $9.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.75
Price Target Upside17.90% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast29.20%
EPS Growth Forecast―